Tropifexor - Novartis

Drug Profile

Tropifexor - Novartis

Alternative Names: LJN452

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antifibrotics; Benzothiazoles; Oxazoles
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Primary bile acid malabsorption; Primary biliary cirrhosis

Most Recent Events

  • 07 May 2018 Novartis Pharmaceuticals plans the TANDEM phase II trial for Non-alcoholic Steatohepatitis in July 2018 , (NCT03517540)
  • 29 Jan 2018 Chemical structure information added
  • 25 Jan 2018 Novartis Pharmaceuticals completes a phase II trial for Primary bile acid malabsorption in USA, United Kingdom and Germany (PO) (NCT02713243)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top